Lorus Therapeutics announces election of three new Directors and appoints a new Chairman



    TORONTO, Sept. 19 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR; AMEX:   LRP),
a biopharmaceutical company specializing in the research and development of
pharmaceutical products and technologies for the management of cancer, today
announced that Dr. Denis Burger, Ms. Susan Koppy and Dr. Mark Vincent were
elected to the Board of Directors of Lorus at the Annual General Meeting on
September 19, 2007. Dr. Burger has been unanimously elected as the Chairman of
the Board by the Board of the Directors.
    Other members returning to Lorus' Board are Herbert Abramson, Chairman
and CEO of Trapeze Capital Corp.; J. Kevin Buchi, EVP and CFO of Cephalon
Inc.; Georg Ludwig, Managing Director of ConPharm Anstalt; Alan A. Steigrod,
Managing Director of Newport Healthcare Ventures; Dr. Jim A. Wright, CEO of
NuQuest Bio Inc.; and Dr. Aiping Young, President and CEO of Lorus
Therapeutics Inc.

    Denis R. Burger

    Dr. Denis R. Burger has co-founded Trinity Biotech plc, based in Dublin,
Ireland in June 1992 and acted as Chairman from 1992 to 1995 and now serves on
the Board of Directors of the Company. Dr. Burger was the past Chairman, Chief
Executive Officer and a director of AVI Biopharma Inc, an Oregon based
biotechnology company. Dr. Burger is also a partner in Sovereign Ventures, a
healthcare consulting and funding firm based in Portland, Oregon. He was a
co-founder and, from 1981 to 1990, Chairman of Epitope Inc. In addition, Dr.
Burger has held a professorship in the Department of Microbiology and
Immunology and Surgery (Surgical Oncology) at the Oregon Health Sciences
University in Portland. Dr. Burger received his Master of Science and PhD in
Microbiology and Immunology from the University of Arizona.

    Susan Koppy

    Susan Koppy is the senior vice president, business and corporate
development of Idenix Pharmaceuticals since January 2006. Prior to joining
Idenix, Ms. Koppy was with Applied Biosystems, Inc. as vice president of
strategy and business development from May 2004 to July 2005. Previously, from
2001-2004, Ms. Koppy served as director of business development for Novartis
Pharmaceuticals AG focusing on its Infectious Diseases Franchise. Prior to
that, since February 2000, Ms. Koppy was Novartis' head of commercial and
business intelligence.

    Mark Vincent

    Dr. Mark Vincent is the co-founder and Chief Executive Officer of
Sarissa, Inc. since 2000. Dr. Vincent has extensive experience as a consultant
to Canadian and U.S. biotech and pharma companies. He served as a Director of
Drug Royalty Corporation and also sits as a member of Scientific Advisory
Board for several biotechnology companies. Dr. Vincent is an Associate
Professor of Oncology at the University of Western Ontario and a staff medical
oncologist at the London Regional Cancer Program.
    "On behalf of the Board of Directors, I am delighted to welcome these
three talented and highly qualified individuals to our Board. They all bring
to Lorus an exceptional level of knowledge and experience in the
pharmaceutical industry, which will contribute to the advancement of our drug
candidates", commented Dr. Aiping Young, President and CEO of Lorus. "The
newly-appointed Directors will provide expertise in areas of clinical
development; facilitating investment and strategic partnering opportunities;
and raising the profile of the Company nationally and internationally. I look
forward to the input of all of our Board members and working with them, to
enhance shareholder value."

    About Lorus

    Lorus is a biopharmaceutical company focused on the research and
development of novel therapeutics in cancer. Lorus' goal is to capitalize on
its research, preclinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination with other
drugs, to successfully manage cancer. Through its own discovery efforts and an
acquisition and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Lorus has completed one Phase II and one Phase III
clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock
Exchange under the symbol LOR, and on the American Stock Exchange under the
symbol LRP.

    Forward looking statements

    This press release contains forward-looking statements within the meaning
of Canadian and U.S. securities laws. Such statements include, but are not
limited to, statements relating to: financings and corporate reorganizations,
the establishment of corporate alliances, the Company's plans, objectives,
expectations and intentions and other statements including words such as
"continue", "expect", "intend", "will", "should", "would", "may", and other
similar expressions. Such statements reflect our current views with respect to
future events and are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered
reasonable by us are inherently subject to significant business, economic,
competitive, political and social uncertainties and contingencies. Many
factors could cause our actual results, performance, achievements or the
transactions described in this press release to be materially different from
any future results, performance, achievements transactions described in this
press release, if at all, that may be expressed or implied by such
forward-looking statements, including, among others: the progress of
negotiations; our ability to obtain regulatory, securityholder and other
approvals; our ability to obtain the capital required for research and
operations; the inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory approval
process; the progress of our clinical trials; our ability to find and enter
into agreements with potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed from
time-to-time in our ongoing quarterly filings, annual information forms,
annual reports and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
    Should one or more of these risks or uncertainties materialize, or should
the assumptions set out in the section entitled "Risk Factors" in our filings
with Canadian securities regulators and the United States Securities and
Exchange Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described herein.
These forward-looking statements are made as of the date of this press release
and we do not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure you
that such statements will prove to be accurate as actual results and future
events could differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not guarantees of
future performance and accordingly investors are cautioned not to put undue
reliance on forward-looking statements due to the inherent uncertainty
therein.

    Lorus Therapeutics Inc.'s recent press releases are available through its
website at www.lorusthera.com.





For further information:

For further information: Enquiries: Lorus Therapeutics Inc., Dr. Saeid
Babaei, (416) 798-1200 ext. 490, ir@lorusthera.com

Organization Profile

Aptose Biosciences Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890